CLINICAL TRIALS PROFILE FOR MINOXIDIL (FOR WOMEN)

505(b)(2) Clinical Trials for Minoxidil (for Women)

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT01325337 ↗	Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia	Completed	Allergan	Phase 2	2011-06-01	This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion except for minoxidil 5% solution which will be provided open-label.
OTC	NCT01325350 ↗	Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss	Completed	Allergan	Phase 2	2011-06-01	This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 2% solution in women with female pattern hair loss. All treatments will be provided in a double-blinded fashion except for minoxidil 2% solution which will be provided open-label.

All Clinical Trials for Minoxidil (for Women)

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00151515 ↗	A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss	Completed	Johnson & Johnson Consumer and Personal Products Worldwide	Phase 3	2003-10-01	The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss. The secondary purpose is to evaluate the safety of a topical 5% minoxidil formulation in males when used twice daily for the treatment of pattern hair loss and to obtain the safety data on the investigational product when used twice daily for up to one year.
NCT00175617 ↗	Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss	Completed	University of British Columbia	Phase 2	2005-09-01	This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
NCT00418730 ↗	Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss	Completed	Neosil, Inc.	Phase 2	2007-01-01	The purpose of this study is to measure the hair growth response to topical NEOSH101 when applied twice daily to the balding scalp for 16 weeks. One hundred eighty men with Norwood/Hamilton grades III-IV with thinning in the top and center of the scalp will participate. Three equally sized treatment groups (60 men each) will receive either topical NEOSH101 2.0%, minoxidil 5%, or placebo.
NCT00607477 ↗	Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension	Terminated	University of Chicago	N/A	2008-01-01	The purpose of this study is to describe the length of time and extent of blood pressure response to minoxidil and hydralazine among cancer patients with difficult-to-treat vascular endothelial growth factor (VEGF) inhibitor treatment induced hypertension.
NCT00876200 ↗	Efficacy of Minoxidil in Children With Williams-Beuren Syndrome	Completed	Hospices Civils de Lyon	Phase 2	2009-03-01	The Williams-Beuren syndrome (WBS) is a sporadic congenital disorder characterized by a multisystem developmental impairment. This syndrome is caused by a microdeletion in chromosome 7q11.23 that encompasses loss of the elastin locus. Elastin, which is part of the extracellular matrix, controls proliferation of vascular smooth muscle cells (VSMCs) and stabilizes arterial structure. Loss of elastin gene in WBS patients has been claimed to provide a biological basis for the abnormal elastic fibre properties leading to cardiovascular abnormalities like supravalvular aortic stenosis (SVAS), hypertension, arteriosclerosis and stenosis in more than 50% of WBS children. These cardiovascular pathologies result in important consequences and neither curative nor preventive medicinal treatments exist at this time. Surgery is needed in more than half cases, while it is often leading to complications. Minoxidil is a well-known antihypertensive drug used in adults and children. Furthermore, according to animal studies, minoxidil seems to increase arterial elastin content by decreasing elastase activity in these tissues. Other data demonstrate that minoxidil specifically stimulate elastin synthesis. Working Hypothesis:If insufficient elastin synthesis leads to vascular complications and arterial hypertension in children with WBS, restoration of sufficient quantity of elastin should then result in prevention or inhibition of vascular malformations and improvement in arterial tension. Therefore, as a pharmacological agent capable to stimulate elastin expression, minoxidil might be a useful drug for the treatment of abnormal elastin metabolism in WBS children. Objective:To evaluate the efficacy of minoxidil on cardiovascular structure in children with Williams Beuren syndrome. Methodology: randomized controlled trial on two parallel group (23 patients in each arm) Main criterion:variation of carotid Intima-media thickness (IMT) before and after 12 months of treatment with Minoxidil versus placebo Secondary intermediate criteria of the vascular properties are arterial stiffness, cardiac and renal stenosis, arterial tension. Total study duration:30 months including a 12 month-recruitment period

Clinical Trial Conditions for Minoxidil (for Women)

Condition Name

Condition Name for Minoxidil (for Women)
Intervention	Trials
Androgenetic Alopecia	26
Alopecia Areata	11
Female Pattern Hair Loss	7
Alopecia	7

Condition MeSH

Condition MeSH for Minoxidil (for Women)
Intervention	Trials
Alopecia	61
Alopecia Areata	51
Hypotrichosis	2
Hypertension	2

Clinical Trial Locations for Minoxidil (for Women)

Trials by Country

Trials by Country for Minoxidil (for Women)
Location	Trials
United States	59
Egypt	13
Thailand	7
Germany	7
France	5

Trials by US State

Trials by US State for Minoxidil (for Women)
Location	Trials
Texas	6
Minnesota	5
Ohio	5
Oregon	4
North Carolina	4

Clinical Trial Progress for Minoxidil (for Women)

Clinical Trial Phase

Clinical Trial Phase for Minoxidil (for Women)
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	8
PHASE2	2

Clinical Trial Status

Clinical Trial Status for Minoxidil (for Women)
Clinical Trial Phase	Trials
Completed	36
Recruiting	18
Not yet recruiting	8

Clinical Trial Sponsors for Minoxidil (for Women)

Sponsor Name

Sponsor Name for Minoxidil (for Women)
Sponsor	Trials
Mae Fah Luang University Hospital	5
Assiut University	5
Applied Biology, Inc.	4

Sponsor Type

Sponsor Type for Minoxidil (for Women)
Sponsor	Trials
Other	66
Industry	32
OTHER_GOV	3

Minoxidil (for Women) Market Analysis and Financial Projection

Last updated: April 27, 2026

MINOXIDIL (FOR WOMEN): Clinical Trials Update, Market Analysis, and Projections

What is the current clinical development status for Minoxidil (for women)?

Minoxidil is an established topical therapy for androgenetic alopecia (female pattern hair loss, FPHL). In the US and most major markets, marketed products for women rely on the same core molecule (minoxidil) and the same clinical endpoint paradigm used historically: hair count increase from baseline over defined treatment periods.

Clinical trial activity in 2024-2026 remains sparse for new minoxidil “women-only” formulations. Most recent late-stage and pivotal-like efforts in minoxidil hair products have tended to be reformulations (vehicle, foam/solution, delivery tech, adjunct dosing regimens) and life-cycle work rather than new mechanism-of-action programs.

Implication for trial watch: if the goal is to identify true “next-wave” competitive differentiation, the highest-probability signals are

• new delivery formats claiming superior deposition or tolerability,
• dosing regimen changes (frequency or concentration),
• combination approaches (minoxidil paired with other active agents),
• and new endpoints or study designs aimed at reducing variability in hair count measurements.

What endpoints and study designs dominate Minoxidil (women) evidence?

Across minoxidil topical studies for women, the clinically accepted readouts include:

• Targeted hair counts (scalp area-based quantification) at baseline and multiple post-treatment timepoints
• Change from baseline in total vellus or terminal hair counts per standardized area
• Timepoints typically structured around 12 to 24 weeks for early efficacy and 48 weeks for more durable response characterization
• Physician global assessment and patient self-assessment as secondary endpoints
• Safety/tolerability focused on local reactions (scalp irritation, dryness, pruritus), and systemic signals consistent with topical exposure

This endpoint framework continues to anchor regulatory expectations and payer and clinician interpretation of comparative value.

---

What does the market look like for Minoxidil (for women) today?

How big is the category and who holds the value?

Minoxidil for women sits inside the broader androgenetic alopecia treatment market, which includes topical minoxidil, oral minoxidil (off-label in many jurisdictions), low-level laser devices, and combination products.

In practice, minoxidil remains the dominant topical anchor because it combines:

• long-established efficacy evidence for FPHL,
• low price per treatment relative to device and combination options,
• and wide availability through pharmacies and e-commerce.

Competitive landscape structure

• Brand-origin minoxidil brands (historic originators and regional brand owners depending on geography)
• Generic minoxidil (solution and foam) driving price compression
• Private label and retailer-branded variants
• Combination and adjacent-asset launches that use minoxidil as the backbone in some jurisdictions

Where is price pressure coming from?

The category has durable brand equity but recurring price competition because:

• minoxidil’s molecule is off-patent in most markets,
• the regulatory path for reformulations often supports faster entry by generics,
• and manufacturing scale favors low unit cost.

Net effect: differentiation tends to move from chemistry to formulation and channel execution.

What does demand look like and what drives growth?

Key demand drivers remain consistent:

• ongoing prevalence of FPHL and high unmet needs for cosmetically meaningful regrowth,
• increasing willingness to use self-directed topical therapy,
• growth in online pharmacy and direct-to-consumer education,
• and clinician adoption of early initiation and persistence.

Growth is constrained by:

• adherence drop-off (topical regimens require continuous use),
• perceived irritation barriers,
• and switching behavior toward combination products or off-label oral minoxidil when patients seek faster visible results.

---

What are the strongest product-level determinants of share for Minoxidil (women)?

Formulation and vehicle matter

Market performance usually tracks formulation attributes tied to adherence and tolerability:

• Foam vs solution: foam is often positioned for reduced dripping and perceived tolerability
• Spray vs dropper application: affects time-to-apply and user compliance
• Propellant and surfactant systems: influence scalp sensation and irritation profiles
• Concentration and frequency: patient experience and labeling constraints influence real-world persistence

Brand trust and channel reach matter

Minoxidil products win through:

• broad pharmacy footprint,
• predictable availability,
• and pharmacy chain promotions plus online retailer bundling.

Where generics compete, packaging clarity and “women-specific” messaging improve conversion even when active ingredients are the same.

---

Market projections: Base case, upside, and downside

How should investors model the next 3 to 7 years?

Given minoxidil’s mature status, the projection logic should be built around:

• unit volume growth driven by FPHL awareness and access,
• price declines due to generic competition,
• and incremental share capture from formulation and channel innovation.

Projection framework (category-level)

• Volume: grows modestly with increased diagnosis and persistence education
• Price: declines in most markets due to generics and private label
• Mix: improved by foam and better-tolerability formulations, plus combination products that include minoxidil

Scenario model (directional)

Because exact unit and revenue numbers depend on geography, channel mix, and brand/generic segmentation not provided in the prompt, the model below stays actionable at the scenario level.

Scenario	Volume trend	Price trend	Competitive mix	Net category revenue trajectory
Downside	Low-single-digit growth	Faster decline	More generic substitution	Flat to low growth
Base case	Mid-single-digit growth	Gradual decline	Mix shifts modestly to foam	Low-to-mid growth
Upside	Higher single- to mid-single-digit growth	Slower decline	Better-tolerability reformulations, stronger DTC	Mid growth

Time horizon: 2025-2031
Driver sensitivity: persistence (adherence) and tolerability improvements are the two highest-leverage factors for sustained unit growth.

---

Key risks and watch items

What could disrupt the market for Minoxidil (women)?

1. Regulatory and labeling updates that restrict or refine women’s use messaging in key markets.
2. Safety/tolerability narratives amplified by social and DTC forums (irritation and shedding perception).
3. Rapid category substitution toward combination topical regimens or oral off-label minoxidil.
4. New topical delivery platforms that reduce irritation and increase compliance, shifting share within the minoxidil class.

What signals to monitor in clinical and competitive intelligence?

• Posting and completion of randomized trials comparing vehicle formats and regimens, especially those measuring early timepoints and tolerability.
• Head-to-head formulations that show improved patient-reported outcomes, not only hair counts.
• Combination development where minoxidil is paired with other actives, changing trial design and payer perception.

---

Key Takeaways

• Minoxidil is mature for female pattern hair loss; clinical differentiation now centers on formulation, tolerability, and regimen, not new mechanism.
• Trial density is lower than in earlier eras; watch for vehicle and delivery improvements and combination regimens rather than monotherapy reinvention.
• The market is still anchored by minoxidil because of proven efficacy, accessibility, and price-to-value, but revenue growth depends on volume uptake vs price compression.
• Projection for 2025-2031 is best modeled as modest volume growth with price pressure, producing low-to-mid growth in most plausible scenarios.

---

FAQs

1. Is minoxidil for women still considered clinically supported? Yes. Its efficacy evidence for FPHL is established and the endpoint framework remains hair count-based assessment with standardized scalp areas.
2. What is the most meaningful differentiation strategy in minoxidil for women? Vehicle and delivery format that improve tolerability and adherence (commonly foam vs solution positioning).
3. Do generics materially change the business outlook? Yes. They compress price and shift competition toward mix, channel execution, and patient preference for tolerability.
4. Which trial endpoints best translate to real-world demand? Hair count change alongside patient-reported tolerability and persistence indicators, since adherence drives long-term outcomes.
5. What is the main threat to minoxidil share? Replacement by combination topical products or patient migration to off-label oral minoxidil when perceived results are faster.

---

References

[1] National Library of Medicine. ClinicalTrials.gov: Minoxidil and female pattern hair loss (search results). (Accessed 2026-04-27). https://clinicaltrials.gov/
[2] FDA. Drug approvals and labeling information for topical minoxidil products. (Accessed 2026-04-27). https://www.accessdata.fda.gov/
[3] PubMed. Minoxidil topical therapy for female pattern hair loss: randomized controlled trials and systematic reviews. (Accessed 2026-04-27). https://pubmed.ncbi.nlm.nih.gov/